Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

por Janni, W, Harbeck, N, Rack, B, Augustin, D, Jueckstock, J, Wischnik, A, Annecke, K, Scholz, C, Huober, J, Zwingers, T, Friedl, T W P, Kiechle, M
Publicado 2016